Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026. Renergen’s Chief Executive Officer, Stefano Marani, has been appointed President, Electronics and Space of ASP Isotopes, and Renergen’s Chief Operating Officer, Nick Mitchell, has been appointed Co-Chief Operating Officer of ASP Isotopes.
The company expects to enter into employment agreements providing Mr. Marani a base salary of $550,000 per year and Mr. Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock. Each executive has been approved for a grant of 700,000 shares of common stock, vesting in eight equal installments over four years, with 87,500 shares vesting on each six‑month anniversary of employment, subject to continued service.
The stock awards are being made under ASP Isotopes’ inducement equity incentive plans in line with Nasdaq Listing Rule 5635(c)(4), and both executives will also be eligible for annual equity awards under the company’s 2022 Equity Incentive Plan. Due to prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement, the company notes that Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest in such dealings for related‑party disclosure purposes.
ASP Isotopes Inc. completed its previously announced acquisition of Renergen Limited on January 6, 2026. ASP Isotopes acquired all issued Renergen ordinary shares via a South African court-approved scheme of arrangement, paying with shares of its own common stock.
Renergen shareholders received 0.09196 ASP Isotopes common shares for each Renergen ordinary share, resulting in the issuance of 14,270,000 new ASP Isotopes shares. Following the deal, Renergen became a direct, wholly owned subsidiary, and its shares will be delisted from the Johannesburg Stock Exchange, the Australian Securities Exchange and A2X, while ASP Isotopes stock remains listed on Nasdaq and the JSE.
Renergen executives are joining ASP Isotopes’ leadership, with CEO Stefano Marani becoming President, Electronics and Space, and COO Nick Mitchell becoming Co-Chief Operating Officer. The consideration shares were issued in an unregistered transaction relying on Rule 802, and ASP Isotopes plans to file required acquired-business financial statements and pro forma information in a later amendment.
ASP Isotopes Inc. reports that the South African Takeover Regulation Panel has issued a compliance certificate for its planned acquisition of Renergen Limited. This clears a key regulatory step so the South African law scheme of arrangement can proceed to implementation. Under the Scheme, Renergen shareholders are to receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The company outlines a detailed timetable through early January 2026, including suspensions of Renergen trading on the JSE and ASX, the listing of ASP Isotopes consideration shares, the Scheme implementation date, settlement of new shares, and payment of cash for fractional entitlements. The disclosure also highlights cross-border settlement mechanics and reiterates risks that the Scheme may not be implemented as anticipated or that expected benefits from the Renergen acquisition may not be realized.
ASP Isotopes Inc. reported that, on December 17, 2025, it obtained all required regulatory approvals and clearances for its proposed offer to acquire all of the issued ordinary shares of Renergen Limited.
The transaction is structured as a scheme of arrangement under South African law, under which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date. The company also issued a press release describing the receipt of these approvals.
ASP Isotopes Inc. reported a leadership update. Founder and Executive Chairman Paul Mann will resume his role as the company’s Chief Executive Officer, while continuing as Executive Chairman, after a temporary leave of absence. His return to the dual role is effective January 19, 2026. The company disclosed this change in connection with a press release dated December 2, 2025.
ASP Isotopes Inc. (ASPI) is asking stockholders to vote at its virtual 2025 annual meeting on December 18, 2025. Investors are being asked to elect two Class III directors, Sipho N. Maseko and Todd Wider, M.D., to new three-year terms and to ratify EisnerAmper LLP as independent auditor for the year ending December 31, 2025. Only holders of common stock at the October 27, 2025 record date, when 110,840,122 shares were outstanding, may vote, with one vote per share.
The company highlights that six of seven directors are Nasdaq‑defined independent and describes an active audit, compensation, and nominating/governance committee structure. A new non‑employee director pay policy provides a $100,000 annual cash retainer plus equity awards. For 2024, Executive Chairman Paul Mann received total compensation of about $4.77 million, including salary, bonus, and restricted stock. Directors and executives together beneficially own 14.4% of outstanding shares.
ASP Isotopes Inc. filed a Form 8-K to furnish an investor presentation connected to its previously announced quarterly business update conference. On November 21, 2025, the company released a "Third Quarter Update Call" presentation, dated as of November 2025, which is attached as Exhibit 99.1. The information in the presentation is provided as of November 2025, and the company states it does not assume any obligation to update it. The material is furnished under Regulation FD and is expressly not deemed "filed" for purposes of certain liability provisions of the federal securities laws.
ASP Isotopes Inc. insider activity: The Interim CEO and COO reported selling 67,500 shares of common stock of ASP Isotopes Inc. on 11/17/2025 at a weighted average price of $7.507 per share. After this transaction, the executive beneficially owns 1,579,693 shares.
The filing explains that the sale was a "sell to cover" transaction made under a Rule 10b5-1 trading plan adopted on June 9, 2025, to cover tax withholding obligations tied to the vesting of restricted stock awards. The shares were sold in multiple trades at prices ranging from $7.215 to $7.85.
ASP Isotopes Inc. (ASPI) reports third-quarter 2025 results reflecting early commercial traction but very heavy losses as it scales its isotope and nuclear fuels platform.
Total revenue reached $4.9 million for the quarter and $7.2 million for the first nine months of 2025, up from $2.95 million a year earlier, driven by both product and new construction services revenue. However, high research and development plus selling, general and administrative costs led to a nine‑month net loss of $96.5 million, compared with $23.2 million in the prior‑year period.
The balance sheet expanded significantly, with cash and cash equivalents of $113.9 million and total assets of $225.9 million as of September 30, 2025, supported by two common stock offerings in June and July 2025 and additional capital raised in October and November. Convertible notes payable at fair value increased to $98.0 million, and total stockholders’ equity rose to $96.6 million.
ASP Isotopes has begun commercial production at two enrichment facilities in South Africa and is preparing initial shipments of enriched C‑12, Si‑28 and C‑14 between late 2025 and the first half of 2026, while also producing Yb‑176 samples. The company is planning additional plants in South Africa, Iceland and the U.S., pursuing a uranium‑235 nuclear fuel initiative, a pending acquisition of Renergen, and a planned spin‑off and U.S. listing of its Quantum Leap Energy (QLE) business, for which a confidential S‑1 has been submitted.
ASP Isotopes Inc. reported that it will host a quarterly business update conference call and webcast on November 21, 2025 at 8:30 a.m. Eastern Time. The company disclosed this plan in a current report and attached the related press release as an exhibit, noting that the call will provide a regular update on its business activities. The press release is furnished for information purposes and is not treated as filed under securities law.
FAQ
What is the current stock price of ASP Isotopes (ASPI)?
What is the market cap of ASP Isotopes (ASPI)?
